Abstract
Background: Obesity associated with high risk of cardiovascular disease and diabetes due
to impairment in glucose and lipid metabolism as well as low grade inflammatory response.
Hypothalamic hypodopaminergic state is observed in obese subject. Accordingly, treatment
with Bromocriptine, a centrally acting dopamine D2-receptor agonist, was reported to
regulate food intake and improve insulin sensitive and glucose tolerance in obese subject.
Aim: The objective of this study is to investigate the potential effect of bromocriptine on
body weight and metabolic parameter as well as the inflammatory response in obese women.
Method: Out of 46 women enrolled in the study, 12 women did not complete study. The
remaining 34 patients divided into two groups Group I: Control group (N=16), this group
advised only for dietary therapy plus life style modifications. Group II: Bromocriptine group
(N=18); The women of this group given 2.5mg bromocriptine at morning once daily for 12
weeks in addition dietary therapy plus life style modifications as in group I.Body weight
(WT) and body mass index (BMI) and Fasting blood glucose level (FBG) , Lipid profile
[total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-C), low-density
lipoprotein (LDL-C)] and inflammatory markers high sensitive C-reactive protein (hsCRP)
and tumor necrosis factor alpha (TNF-α) were measured before and after 12 weeks of the
treatment.
to impairment in glucose and lipid metabolism as well as low grade inflammatory response.
Hypothalamic hypodopaminergic state is observed in obese subject. Accordingly, treatment
with Bromocriptine, a centrally acting dopamine D2-receptor agonist, was reported to
regulate food intake and improve insulin sensitive and glucose tolerance in obese subject.
Aim: The objective of this study is to investigate the potential effect of bromocriptine on
body weight and metabolic parameter as well as the inflammatory response in obese women.
Method: Out of 46 women enrolled in the study, 12 women did not complete study. The
remaining 34 patients divided into two groups Group I: Control group (N=16), this group
advised only for dietary therapy plus life style modifications. Group II: Bromocriptine group
(N=18); The women of this group given 2.5mg bromocriptine at morning once daily for 12
weeks in addition dietary therapy plus life style modifications as in group I.Body weight
(WT) and body mass index (BMI) and Fasting blood glucose level (FBG) , Lipid profile
[total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL-C), low-density
lipoprotein (LDL-C)] and inflammatory markers high sensitive C-reactive protein (hsCRP)
and tumor necrosis factor alpha (TNF-α) were measured before and after 12 weeks of the
treatment.